Eli Non Current Liabilities Total vs Accounts Payable Analysis

LLY Stock

USD 749.92 3.49 0.46%

Eli Lilly financial indicator trend analysis is much more than just examining Eli Lilly latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eli Lilly is a good investment. Please check the relationship between Eli Lilly Non Current Liabilities Total and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Non Current Liabilities Total vs Accounts Payable

Non Current Liabilities Total vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eli Lilly Non Current Liabilities Total account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Eli Lilly's Non Current Liabilities Total and Accounts Payable is 0.8. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Eli Lilly and, assuming nothing else is changed. The correlation between historical values of Eli Lilly's Non Current Liabilities Total and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Eli Lilly and are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Non Current Liabilities Total i.e., Eli Lilly's Non Current Liabilities Total and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Non Current Liabilities Total

Accounts Payable

An accounting item on the balance sheet that represents Eli Lilly obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Eli Lilly are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Eli Lilly's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.32 in 2024, whereas Selling General Administrative is likely to drop slightly above 5.7 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	21.0B	21.9B	27.0B	28.4B
Total Revenue	28.3B	28.5B	34.1B	35.8B

Gross Profit Total Revenue

Eli Lilly fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Other Current Liab	Short Term Debt	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.93	0.94	0.11	0.76	0.83	0.08	0.21	0.99	0.45	0.13	0.94	-0.75	0.85	0.96	0.85	0.59	0.95	0.97	0.74	0.79	0.72	0.96	0.82	-0.13	-0.27
Short Long Term Debt Total	0.93		0.95	-0.25	0.61	0.96	-0.28	-0.02	0.91	0.39	-0.14	0.97	-0.9	0.92	0.92	0.95	0.6	0.99	0.9	0.79	0.84	0.75	0.94	0.85	-0.14	-0.53
Total Current Liabilities	0.94	0.95		-0.02	0.62	0.91	-0.09	0.0	0.92	0.36	-0.06	0.97	-0.78	0.76	0.94	0.94	0.43	0.93	0.92	0.68	0.82	0.88	0.97	0.91	-0.16	-0.36
Total Stockholder Equity	0.11	-0.25	-0.02		0.33	-0.34	0.97	0.46	0.13	0.06	0.62	-0.1	0.47	-0.33	0.06	-0.29	-0.2	-0.19	0.09	-0.18	-0.21	0.02	0.03	-0.07	0.01	0.75
Property Plant And Equipment Net	0.76	0.61	0.62	0.33		0.52	0.3	0.28	0.77	0.44	0.23	0.64	-0.46	0.64	0.69	0.49	0.63	0.67	0.7	0.62	0.48	0.38	0.68	0.51	-0.09	-0.01
Net Debt	0.83	0.96	0.91	-0.34	0.52		-0.4	-0.29	0.85	0.22	-0.38	0.93	-0.94	0.84	0.87	0.95	0.57	0.93	0.77	0.83	0.81	0.73	0.91	0.88	-0.1	-0.58
Retained Earnings	0.08	-0.28	-0.09	0.97	0.3	-0.4		0.57	0.09	0.05	0.73	-0.18	0.53	-0.31	0.03	-0.37	-0.23	-0.22	0.06	-0.21	-0.32	-0.05	-0.03	-0.2	0.01	0.81
Cash	0.21	-0.02	0.0	0.46	0.28	-0.29	0.57		0.11	0.42	0.96	-0.04	0.3	0.11	0.09	-0.17	0.0	0.06	0.34	-0.22	-0.09	0.0	-0.02	-0.21	-0.2	0.4
Non Current Assets Total	0.99	0.91	0.92	0.13	0.77	0.85	0.09	0.11		0.41	0.06	0.93	-0.78	0.85	0.95	0.83	0.62	0.94	0.92	0.8	0.77	0.68	0.96	0.82	-0.1	-0.26
Non Currrent Assets Other	0.45	0.39	0.36	0.06	0.44	0.22	0.05	0.42	0.41		0.24	0.37	-0.29	0.43	0.29	0.33	0.42	0.43	0.49	0.04	0.48	0.24	0.29	0.29	0.02	-0.39
Cash And Short Term Investments	0.13	-0.14	-0.06	0.62	0.23	-0.38	0.73	0.96	0.06	0.24		-0.14	0.45	-0.05	0.04	-0.28	-0.15	-0.06	0.24	-0.28	-0.25	-0.02	-0.08	-0.29	-0.13	0.63
Net Receivables	0.94	0.97	0.97	-0.1	0.64	0.93	-0.18	-0.04	0.93	0.37	-0.14		-0.87	0.85	0.93	0.95	0.61	0.96	0.92	0.78	0.91	0.74	0.97	0.94	-0.19	-0.48
Common Stock Shares Outstanding	-0.75	-0.9	-0.78	0.47	-0.46	-0.94	0.53	0.3	-0.78	-0.29	0.45	-0.87		-0.89	-0.76	-0.87	-0.75	-0.89	-0.69	-0.84	-0.85	-0.5	-0.8	-0.8	0.04	0.73
Non Current Liabilities Total	0.85	0.92	0.76	-0.33	0.64	0.84	-0.31	0.11	0.85	0.43	-0.05	0.85	-0.89		0.81	0.81	0.78	0.95	0.83	0.81	0.78	0.46	0.8	0.66	-0.1	-0.55
Inventory	0.96	0.92	0.94	0.06	0.69	0.87	0.03	0.09	0.95	0.29	0.04	0.93	-0.76	0.81		0.85	0.52	0.93	0.93	0.75	0.75	0.77	0.96	0.83	-0.03	-0.24
Other Current Assets	0.85	0.95	0.94	-0.29	0.49	0.95	-0.37	-0.17	0.83	0.33	-0.28	0.95	-0.87	0.81	0.85		0.47	0.93	0.84	0.68	0.87	0.78	0.91	0.89	-0.17	-0.6
Other Stockholder Equity	0.59	0.6	0.43	-0.2	0.63	0.57	-0.23	0.0	0.62	0.42	-0.15	0.61	-0.75	0.78	0.52	0.47		0.66	0.51	0.76	0.7	0.02	0.53	0.51	0.0	-0.49
Total Liab	0.95	0.99	0.93	-0.19	0.67	0.93	-0.22	0.06	0.94	0.43	-0.06	0.96	-0.89	0.95	0.93	0.93	0.66		0.93	0.8	0.85	0.69	0.94	0.83	-0.13	-0.49
Total Current Assets	0.97	0.9	0.92	0.09	0.7	0.77	0.06	0.34	0.92	0.49	0.24	0.92	-0.69	0.83	0.93	0.84	0.51	0.93		0.61	0.79	0.74	0.91	0.79	-0.18	-0.27
Intangible Assets	0.74	0.79	0.68	-0.18	0.62	0.83	-0.21	-0.22	0.8	0.04	-0.28	0.78	-0.84	0.81	0.75	0.68	0.76	0.8	0.61		0.65	0.37	0.79	0.7	-0.17	-0.4
Other Current Liab	0.79	0.84	0.82	-0.21	0.48	0.81	-0.32	-0.09	0.77	0.48	-0.25	0.91	-0.85	0.78	0.75	0.87	0.7	0.85	0.79	0.65		0.53	0.82	0.89	-0.15	-0.65
Short Term Debt	0.72	0.75	0.88	0.02	0.38	0.73	-0.05	0.0	0.68	0.24	-0.02	0.74	-0.5	0.46	0.77	0.78	0.02	0.69	0.74	0.37	0.53		0.77	0.74	-0.19	-0.18
Accounts Payable	0.96	0.94	0.97	0.03	0.68	0.91	-0.03	-0.02	0.96	0.29	-0.08	0.97	-0.8	0.8	0.96	0.91	0.53	0.94	0.91	0.79	0.82	0.77		0.9	-0.17	-0.34
Property Plant And Equipment Gross	0.82	0.85	0.91	-0.07	0.51	0.88	-0.2	-0.21	0.82	0.29	-0.29	0.94	-0.8	0.66	0.83	0.89	0.51	0.83	0.79	0.7	0.89	0.74	0.9		-0.17	-0.47
Common Stock Total Equity	-0.13	-0.14	-0.16	0.01	-0.09	-0.1	0.01	-0.2	-0.1	0.02	-0.13	-0.19	0.04	-0.1	-0.03	-0.17	0.0	-0.13	-0.18	-0.17	-0.15	-0.19	-0.17	-0.17		0.14
Short Term Investments	-0.27	-0.53	-0.36	0.75	-0.01	-0.58	0.81	0.4	-0.26	-0.39	0.63	-0.48	0.73	-0.55	-0.24	-0.6	-0.49	-0.49	-0.27	-0.4	-0.65	-0.18	-0.34	-0.47	0.14

Click cells to compare fundamentals

Eli Lilly Account Relationship Matchups

Eli Lilly fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.3B	46.6B	48.8B	49.5B	64.0B	67.2B
Short Long Term Debt Total	15.8B	16.6B	16.9B	16.2B	25.2B	26.5B
Total Current Liabilities	11.8B	12.5B	15.1B	17.1B	27.3B	28.7B
Total Stockholder Equity	2.6B	5.6B	9.0B	10.6B	10.8B	9.0B
Property Plant And Equipment Net	8.4B	8.7B	9.0B	10.1B	12.9B	6.8B
Net Debt	13.5B	12.9B	13.1B	14.2B	22.4B	23.5B
Retained Earnings	4.9B	7.8B	9.0B	10.0B	10.3B	9.5B
Cash	2.3B	3.7B	3.8B	2.1B	2.8B	3.1B
Non Current Assets Total	25.6B	29.2B	30.4B	31.5B	38.3B	40.2B
Non Currrent Assets Other	2.3B	3.5B	4.1B	4.3B	5.0B	2.9B
Cash And Short Term Investments	2.4B	3.7B	3.9B	2.2B	2.9B	3.7B
Net Receivables	5.5B	6.9B	8.1B	8.6B	11.3B	11.9B
Common Stock Shares Outstanding	935.7M	912.5M	911.7M	904.6M	903.3M	868.4M
Liabilities And Stockholders Equity	39.3B	46.6B	48.8B	49.5B	64.0B	67.2B
Non Current Liabilities Total	24.8B	28.3B	24.6B	21.6B	25.8B	27.1B
Inventory	3.2B	4.0B	3.9B	4.3B	5.8B	6.1B
Other Current Assets	2.5B	2.9B	2.5B	3.0B	5.7B	6.0B
Other Stockholder Equity	3.6B	6.7B	6.8B	6.9B	4.2B	2.5B
Total Liab	36.6B	40.8B	39.7B	38.7B	53.1B	55.8B
Total Current Assets	13.7B	17.5B	18.5B	18.0B	25.7B	27.0B
Intangible Assets	6.6B	7.5B	7.7B	7.2B	6.9B	7.3B
Other Current Liab	2.2B	10.4B	11.7B	13.2B	13.9B	14.6B
Short Term Debt	1.5B	8.7M	1.5B	1.5B	6.9B	7.2B
Accounts Payable	1.4B	1.6B	1.7B	1.9B	2.6B	2.7B
Property Plant And Equipment Gross	8.4B	8.7B	19.0B	20.4B	24.0B	25.2B
Accumulated Other Comprehensive Income	(6.5B)	(6.5B)	(4.3B)	(3.8B)	(4.3B)	(4.5B)
Common Stock Total Equity	661M	598.8M	598.2M	594.1M	534.7M	494.1M
Short Term Investments	101M	24.2M	90.1M	144.8M	109.1M	103.6M
Capital Stock	598.8M	598.2M	596.3M	594.1M	593.6M	544.7M
Common Stock	598.8M	598.2M	596.3M	594.1M	593.6M	544.7M
Other Liab	10.5B	11.0B	8.7B	6.1B	7.0B	5.5B
Other Assets	4.7B	9.3B	6.4B	7.1B	8.2B	4.2B
Long Term Debt	13.8B	16.6B	15.3B	14.7B	18.3B	19.2B
Treasury Stock	(60.8M)	(55.7M)	(52.7M)	(50.5M)	(44.2M)	(46.4M)
Property Plant Equipment	7.9B	8.7B	9.0B	10.1B	11.7B	8.5B
Good Will	3.7B	3.8B	3.9B	4.1B	4.9B	2.9B
Current Deferred Revenue	6.7B	8.1B	8.8B	14.5B	16.7B	17.5B
Noncontrolling Interest In Consolidated Entity	92.2M	183.6M	175.6M	125.6M	91.8M	141.7M
Retained Earnings Total Equity	13.9B	11.4B	4.9B	10.0B	11.5B	10.8B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eli Non Current Liabilities Total vs Accounts Payable Analysis

Non Current Liabilities Total vs Accounts Payable

Non Current Liabilities Total vs Accounts Payable Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Accounts Payable

Eli Lilly fundamental ratios Correlations

Eli Lilly Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eli Lilly fundamental ratios Accounts

Also Currently Popular

Additional Tools for Eli Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Short Long Term Debt Total
Total Current Assets	+ 0.97	Total Assets
Net Receivables	+ 0.97	Short Long Term Debt Total
Net Receivables	+ 0.97	Total Current Liabilities
Accounts Payable	+ 0.97	Total Current Liabilities

Common Stock Shares Outstanding	- 0.94	Net Debt
Common Stock Shares Outstanding	- 0.9	Short Long Term Debt Total
Total Liab	- 0.89	Common Stock Shares Outstanding
Non Current Liabilities Total	- 0.89	Common Stock Shares Outstanding
Other Current Assets	- 0.87	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.87	Net Receivables